Biocon Ltd
NSE:BIOCON

Watchlist Manager
Biocon Ltd Logo
Biocon Ltd
NSE:BIOCON
Watchlist
Price: 331.5 INR 2.6% Market Closed
Market Cap: 398B INR
Have any thoughts about
Biocon Ltd?
Write Note

Biocon Ltd
Other Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Biocon Ltd
Other Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Biocon Ltd
NSE:BIOCON
Other Receivables
â‚ą10.3B
CAGR 3-Years
213%
CAGR 5-Years
N/A
CAGR 10-Years
24%
Bharat Immunologicals and Biologicals Corporation Ltd
BSE:524663
Other Receivables
â‚ą0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Transgene Biotek Ltd
BSE:526139
Other Receivables
â‚ą0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Z
Zenotech Laboratories Ltd
BSE:532039
Other Receivables
â‚ą16m
CAGR 3-Years
124%
CAGR 5-Years
38%
CAGR 10-Years
33%
Hester Biosciences Ltd
NSE:HESTERBIO
Other Receivables
â‚ą57.9m
CAGR 3-Years
-32%
CAGR 5-Years
71%
CAGR 10-Years
N/A
Panacea Biotec Ltd
NSE:PANACEABIO
Other Receivables
â‚ą31.8m
CAGR 3-Years
17%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Biocon Ltd
Glance View

Market Cap
398B INR
Industry
Biotechnology

Biocon Ltd. is a holding company, which engages in the manufacture, research, and development of therapeutic drugs. The company is headquartered in Bangalore, Karnataka and currently employs 3,203 full-time employees. The company went IPO on 2004-04-17. The firm is also focused on developing novel therapies for diabetes, oncology and immunology. The Company’s businesses segment includes Generics, Biosimilars, Novel Biologics and Research Services. The Company’s Generic Formulations and active pharmaceutical ingredients (API)products include Rosuvastatin, Simvastatin, Atorvastatin, Fingolimod, Dapagliflozin, Pemetrexed, Simvastatin, Atorvastatin, Rosuvastatin, Dabigatran, Apixaban, Vildagliptin, Linagliptin, Empagliflozin, Repaglinide, Liraglutide, Sirolimus, Pimecrolimus, Mycophenolate Mofetil (MMF), Glatiramer Acetate, Fingolimod, Teriflunomide, Dasatinib, Lenalidomide, Pazopanib, Erdafitinib Orlistat, Mirabegron, Posaconazole, Micafungin, Anidulafungin and Brinzolamide. The Company’s portfolio includes ALZUMAb-L (Itolizumab), RemWin (Remdesivir), ARAFLU (Favipiravir) and CytoSorb.

BIOCON Intrinsic Value
455.48 INR
Undervaluation 27%
Intrinsic Value
Price

See Also

What is Biocon Ltd's Other Receivables?
Other Receivables
10.3B INR

Based on the financial report for Sep 30, 2024, Biocon Ltd's Other Receivables amounts to 10.3B INR.

What is Biocon Ltd's Other Receivables growth rate?
Other Receivables CAGR 10Y
24%

The average annual Other Receivables growth rates for Biocon Ltd have been 213% over the past three years , and 24% over the past ten years .

Back to Top